(61 days)
Not Found
No
The device description details a biochemical immunoassay using SPR technology for quantitative measurement. There is no mention of AI or ML in the device description, intended use, or performance studies.
No
The device is an in vitro diagnostic (IVD) assay designed to aid in the diagnosis of myocardial infarction by measuring myoglobin levels, rather than directly treating or preventing a disease.
Yes
The "Intended Use / Indications for Use" section explicitly states that the device "is intended to be used as an aid in diagnosing myocardial infarction".
No
The device description clearly outlines a hardware-based immunoassay using surface plasmon resonance (SPR) and physical reagents (antibodies, enzyme conjugate, wash solution). It is not solely software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's an "aid in diagnosing myocardial infarction in patients exhibiting chest pain." This indicates it's used to analyze a sample taken from the human body to provide information for diagnostic purposes.
- Device Description: The description details a "sandwich immunoassay" and measures "myoglobin in serum." Serum is a biological sample taken from the body. The assay is a laboratory test performed outside the body (in vitro).
- Performance Data: The document includes summaries of both non-clinical and clinical performance data, which are typical for IVD devices to demonstrate their analytical and clinical validity.
- Predicate Device: The mention of a predicate device (OPUS® Myoglobin assay) which is also an IVD further supports this classification.
Therefore, based on the provided information, the Quantech Myoglobin Assay clearly fits the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Quantech Myoglobin Assay is intended to be used as an aid in diagnosing myocardial infarction in patients exhibiting chest pain. It is intended to be used in conjunction with EKG, and physician examination, as well as possibly other biochemical blood tests to rule in or out origin of the chest pain.
Product codes (comma separated list FDA assigned to the subject device)
DRD
Device Description
The Quantech Myoglobin Assay is based on the principle of two site, or sandwich immunoassay in combination with SPR surface mass measurement. Each test module contains a solid phase anti-myoglobin monoclonal antibody immobilized onto a gold surface. An anti-myoglobin enzyme conjugate solution and wash solution are used to enhance the specific detection of myoglobin.
The Quantech assay utilizes myoglobin-specific antibody to capture the myoglobin in the This is followed by a quantitation of the surface mass increase using surface sample. plasmon resonance (SPR), to measure the myoglobin in serum.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Summary of Non-Clinical Performance Data
Dilution Linearity/Parallelism - The parallelism study was conducted to evaluate the linearity of the Quantech MYOGLOBIN Assay. Serum samples were separately spiked with myoglobin and serially diluted with corresponding unspiked serum. The average percent of expected was 107% with individuals varying from 101-115%.
Recovery - Accuracy of the Quantech MYOGLOBIN Assay was calculated from test results as the percentage of added analyte, corrected for endogenous analyte, recovered by the assay. After correcting for endogenous myoglobin content, the average recovery was 108%.
Analytical Sensitivity - Multiple duplicates of zero samples (blank) were assayed to determine the minimum quantity of myoglobin detectable by the Quantech Assay. The average SPR signal shift plus two standard deviations (2 S.D.) was calculated and translated into a dose. The calculated analytical sensitivity of the Quantech myoglobin assay is 6 ng/mL.
Precision - INTRAASSAY variation was calculated by replicate evaluation of three levels of sera in one day. The mean mvoolobin concentrations (with % C.V.) were 61 (11.9%), 131 (9.7%), and 378 (9.5%) ng/mL for the low, medium and high pools, respectively.
The INTERASSAY precision was determined by evaluating three pools (different from INTRAASSAY pools) in multiplicate on different days. The mean myoglobin concentrations (with % C.V.) were 51 (7.1%), 110 (6.2%), and 219 (10.3%) ng/mL for the low, medium and high pools, respectively.
Interfering Substances - Physiological interference was evaluated by spiking a serum pool of myoglobin with bilirubin, triglycerides and hemoglobin at levels ten times the highest expected physiological concentration. The percent recovery of myoglobin was determined to be acceptable in all three solutions and no interference was noted by the endogenous in the Quantech Myoglobin assay.
Hook Effect - Samples well beyond the standard curve range were assayed. No high dose hook effect was observed. Therefore, the Quantech Myoglobin Assay does not give erroneously low results for grossly elevated samples up to at least 10,000 ng/ml.
Summary of Clinical Performance Data
Normal Range - Testing of apparently healthy individuals demonstrated a normal range consistent with published literature (male 19-92 ng/mL and female 12-76 ng/mL). The overall normal range observed with the Quantech MYOGLOBIN assay was 14-70 ng/mL with 16-70 ng/mL for males and 17-55 ng/mL observed for females.
Patient Sample Correlation - Results from human samples with values distributed throughout the quantitative range of the Quantech MYOGLOBIN Assay, were compared with those obtained with a commercially available method (fluorogenic ELISA). The correlation coefficient was 0.970 (slope = 1.16, y-intercept = 7.94 ng/mL).
Conclusions Drawn From Performance Tests
The Quantech Myoglobin Assay provides results which are internally accurate, unaffected by ordinary variation of sample matrix and equivalent to the results obtained using the approved device in a valid laboratory setting.
Additionally, both clinically-based studies (normal range, patient correlation) demonstrated essential equivalence between the two devices as measured by their correlation and the degree to which assay results are linearly related to one another over a broad range of values. Likewise, the normal range evaluation provided empirical evidence that the log of the assay value is statistically similar for both devices, and in agreement with published data.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.5680 Myoglobin immunological test system.
(a)
Identification. A myoglobin immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the myoglobin (an oxygen storage protein found in muscle) in serum and other body fluids. Measurement of myoglobin aids in the rapid diagnosis of heart or renal disease.(b)
Classification. Class II (performance standards).
0
510(k) SUMMARY
Revision 02
Company Information
Quantech Ltd. 1419 Energy Park Drive St. Paul, MN, (612) 647-6370 Thomas Witty, Ph.D. - Vice President, Research and Development
Contact Information
Robin J. Hellen, M.S. Hellen Professional Services (818) 709-5646
Product Name
Classification Name: Trade Name: Common Name:
Myoglobin Immunological Test System, Class II Quantech Myoglobin Assay Mvoalobin Test Kit
· Substantial Equivalence
The Quantech Myoglobin Assay is substantially equivalent to the OPUS® Myoglobir assay marketed by Behring Diagnostics Inc. since 1991.
Intended Use
The Quantech Myoglobin Assay is intended to be used as an aid in diagnosing myocardial infarction in patients exhibiting chest pain. It is intended to be used in conjunction with EKG, and physician examination, as well as possibly other biochemical blood tests to rule in or out origin of the chest pain.
Device Description
The Quantech Myoglobin Assay is based on the principle of two site, or sandwich immunoassay in combination with SPR surface mass measurement. Each test module contains a solid phase anti-myoglobin monoclonal antibody immobilized onto a gold surface. An anti-myoglobin enzyme conjugate solution and wash solution are used to enhance the specific detection of myoglobin.
The Quantech assay utilizes myoglobin-specific antibody to capture the myoglobin in the This is followed by a quantitation of the surface mass increase using surface sample. plasmon resonance (SPR), to measure the myoglobin in serum.
1
Comparison of Technological Characteristics
The Quantech Myoglobin Assay is similar to the Opus® Myoglobin assay (K915850) as follows. Both assays are in vitro immunological assays for the quantitative measurement of human myoglobin. Additionally, both assays use antibody to myoglobin coated on a solid support, and both instruments utilize a microprocessor for instrument control, data acquisition, and data reduction.
Summary of Non-Clinical Performance Data
Dilution Linearity/Parallelism - The parallelism study was conducted to evaluate the linearity of the Quantech MYOGLOBIN Assay. Serum samples were separately spiked with myoglobin and serially diluted with corresponding unspiked serum. The average percent of expected was 107% with individuals varying from 101-115%.
Recovery - Accuracy of the Quantech MYOGLOBIN Assay was calculated from test results as the percentage of added analyte, corrected for endogenous analyte, recovered by the assay. After correcting for endogenous myoglobin content, the average recovery was 108%.
Analytical Sensitivity - Multiple duplicates of zero samples (blank) were assayed to determine the minimum quantity of myoglobin detectable by the Quantech Assay. The average SPR signal shift plus two standard deviations (2 S.D.) was calculated and translated into a dose. The calculated analytical sensitivity of the Quantech myoglobin assay is 6 ng/mL.
Precision - INTRAASSAY variation was calculated by replicate evaluation of three levels of sera in one day. The mean mvoolobin concentrations (with % C.V.) were 61 (11.9%), 131 (9.7%), and 378 (9.5%) ng/mL for the low, medium and high pools, respectively.
The INTERASSAY precision was determined by evaluating three pools (different from INTRAASSAY pools) in multiplicate on different days. The mean myoglobin concentrations (with % C.V.) were 51 (7.1%), 110 (6.2%), and 219 (10.3%) ng/mL for the low, medium and high pools, respectively.
Interfering Substances - Physiological interference was evaluated by spiking a serum pool of myoglobin with bilirubin, triglycerides and hemoglobin at levels ten times the highest expected physiological concentration. The percent recovery of myoglobin was determined to be acceptable in all three solutions and no interference was noted by the endogenous in the Quantech Myoglobin assay.
Hook Effect - Samples well beyond the standard curve range were assayed. No high dose hook effect was observed. Therefore, the Quantech Myoglobin Assay does not give erroneously low results for grossly elevated samples up to at least 10,000 ng/ml.
2
Summary of Clinical Performance Data
Normal Range - Testing of apparently healthy individuals demonstrated a normal range consistent with published literature (male 19-92 ng/mL and female 12-76 ng/mL). The overall normal range observed with the Quantech MYOGLOBIN assay was 14-70 ng/mL with 16-70 ng/mL for males and 17-55 ng/mL observed for females.
Patient Sample Correlation - Results from human samples with values distributed throughout the quantitative range of the Quantech MYOGLOBIN Assay, were compared with those obtained with a commercially available method (fluorogenic ELISA). The correlation coefficient was 0.970 (slope = 1.16, y-intercept = 7.94 ng/mL).
Conclusions Drawn From Performance Tests
The Quantech Myoglobin Assay provides results which are internally accurate, unaffected by ordinary variation of sample matrix and equivalent to the results obtained using the approved device in a valid laboratory setting.
Additionally, both clinically-based studies (normal range, patient correlation) demonstrated essential equivalence between the two devices as measured by their correlation and the degree to which assay results are linearly related to one another over a broad range of values. Likewise, the normal range evaluation provided empirical evidence that the log of the assay value is statistically similar for both devices, and in agreement with published data.
3
Image /page/3/Picture/1 description: The image is a black and white logo for the Department of Health & Human Services - USA. The logo consists of a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of an eagle or bird-like figure, with its wings spread.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
JUN 2 9 1000
Quantech, Ltd. C/O Robin J. Hellen, M.S. Hellen Professional Services 9418 Lasaine Avenue Northridge, California 91325
K981536 Re : Quantech Myoglobin Assay Regulatory Class: II Product Code: DRD April 28, 1998 Dated: Received: April 29, 1998
Dear Ms. Hellen:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions aqainst misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical General requlation (21 CFR Part 820) and that, Devices: through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory In addition, FDA may publish further announcements action. concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or requlations.
4
Page 2
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "dsmo@fdadr.cdrh.fda.gov".
Sincerely yours,
Steven Autman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
DUANTECH MYOGLOBIN ASSAY emarket Notification
PART I - 510(k) Information
Statement for Indications for Use 111.
510(k) Number (if known): K981536
Device Name: Quantech Myoglobin Assay
Indications for Use:
The Quantech Myoglobin Assay is intended to be used as an aid in
diagnosing myocardial infarction in patients exhibiting chest pain. It is
intended to be used in conjunction with EKG, and physician examination,
as well as possibly other biochemical blood tests to rule in or out non-
cardiac damaging origin of the chest pain.
Concurrence of the CDRH, Office of Device Evaluat=ion (ODE)
Prescription Use: ✓
OR
Over the Counter Use: __
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K981536